Novartis not to rush ahead of upcoming patent expirations, RBC says
RBC Capital Markets analysts say Novartis shouldn’t rush to cover upcoming patent expirations, arguing recent clinical-trial setbacks require bringing the rest of its pipeline to market with a high standard and possibly seeking deals.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.